On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Age, Comorbidity, Time on Chemotherapy Predict Increases in Hospitalizations, ER Visits Among CLL Patients

Researchers identified several risk factors leading to greater health-care resource use, including age, comorbidity burden, presence of adverse events, and duration of therapy, in...

Nilotinib Improves Prognosis in Elderly Patients with Ph+ ALL

For the difficult-to-treat elderly population (aged ≥55 years) with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL), combining age-adapted, low-intensity chemotherapy with nilotinib is...

Age, Sex, Timing of Treatment Response Predict Avascular Necrosis in Children with ALL

Avascular necrosis (AVN), a disorder resulting from a temporary or permanent loss of blood supply to the bone, is one of the most serious...
On location

Ibrutinib Well Tolerated in Patients With Central Nervous System Lymphoma

CHICAGO--With few treatment options available for central nervous system lymphoma (CNSL), patients with recurrent/refractory disease typically have poor outcomes, with response rates ranging between...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat a patient with nodular...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

2014 ASH Annual Meeting: Late But Certainly Not Least…

This year’s six late-breaking abstracts feature innovative research in preventing bleeding risk, better prediction tools in Hodgkin lymphoma, and new approaches for high-risk, difficult-to-treat...

Mechanisms of Ibrutinib Resistance Varied in ABC DLBCL

Lymphoma cells may develop resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib using a variety of potentially druggable pathways, opening the door to...

Early Data Show EZH2 Inhibitor Active in Non-Hodgkin Lymphoma

The EZH2 inhibitor EPZ-6438 appears to be a well-tolerated drug and is showing early evidence of anti-lymphoma activity in patients with non-Hodgkin lymphoma of...

Potent Small-Molecule BCL6 Inhibitor Active against ABC-, GCB-DLBCL Cells

Researchers have identified a novel, potent, and specific BCL6 inhibitor that effectively inhibited tumor growth in vitro and in vivo in activated B-cell (ABC)...

ASH Meeting on Lymphoma Biology: Creating a Roadmap for Future Research

More than 350 lymphoma experts from around the world convened at the American Society of Hematology’s first Meeting on Lymphoma Biology to share cutting-edge...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.